Return to Current Article

Kythera Newsroom

KYTHERA Biopharmaceuticals, Inc. Selected To Present At Insideventure’s Debut Investor Conference, March 25-26, Santa Barbara, CA

March 24, 2009

Los Angeles, CA – March 24, 2009 – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that Keith Leonard, President and CEO, will present at InsideVenture’s Debut Conference, March 25-26, 2009 in Santa Barbara, California. KYTHERA has been selected from over 170 nominations to be one of 50 top private companies showcased to long-term investors through presentations and 1-on-1 meetings at the invitation only conference. KYTHERA is a privately held biopharmaceutical company focused on developing and commercializing novel products in aesthetic medicine. The company aims to use the new financing platform to support additional private funding efforts. InsideVenture’s Selection Boards includes Founders and Partners of leading venture firms including NEA, Venrock, DCM, Domain, Frazier, Clarus, Oak Investment, Aisling, and Versant. Over 130 investors are represented in the selected companies.

“We are honored to support KYTHERA in their private funding efforts through our online platform and at our debut transactional conference in Santa Barbara,” said Mona DeFrawi, Chief Executive Officer of InsideVenture. “InsideVenture was created as a powerful and cost-effective platform to support the companies that grow our economy by facilitating their late stage and pre-IPO financing needs. Structural changes in the capital markets over the past 10 years have blocked the real path to economic growth by challenging the financing of the companies delivering valuable new products, jobs and profits for the world economy. These top 50 companies have invested in innovation, and now InsideVenture is innovating the investment process to support their continued growth.”

KYTHERA announced in February that its investors elected early to exercise their rights to invest an additional $10 million as a part of a $40 million Series C financing. “We look forward to building relationships with high quality private investors through InsideVenture’s new financing platform with a goal of further supporting our progress into late stage trials for ATX-101, an adipolytic agent for the reduction in small volumes of localized fat deposits,” said Keith Leonard, President and CEO.

KYTHERA is one of 50 top late-stage private healthcare and technology companies seeking to raise $20-200+M or establish and develop relationships with new investors prior to an eventual IPO. The companies will present their businesses to qualified institutional buyers (QIBs), including mutual fund managers, crossover funds, late stage VC & PE funds and strategic corporate investors. Investors interested in attending the conference may apply for an InsideVenture trial membership; the conference is exclusive to members and by invitation only. The theme of this year’s conference is “Investing in Innovation: Innovation in Investing.” Investors should contact InsideVenture today to apply for membership and an invitation to the InsideVenture Investor Conference, March 25-26, 2009 in Santa Barbara, California.